We offer drug product development through a highly skilled scientific team with expertise in variety of dosage forms like oral, parenteral and topical. We specialize in pediatric dosage forms, fixed dose combinations and modified-release dosage forms. We also support for development of customized formulations for animals. Our team has extensive experience in developing complex formulations and provide tailored solutions to optimize the development time and costs.
Our team is committed to delivering quality results in a time-bound and cost-effective manner at each stage of the development process. Customers also select us, to evaluate container closure systems, storage, and transportation conditions.
ICH-compliant stability studies along with a range of conditions to cover various climatic zones across the globe, help in making decisions early in the drug development cycle.
With decades of experience in formulation development, our scientists look forward to accelerating the time to market of your molecule.
Solid Orals
- Immediate-release tablets (chewable tablets, orally disintegrating tablets, sublingual tablets and bi-layer tablets)
- Modified release tablets (Monolayer, bilayer and mini tablets)
- Fixed dose combinations (Monolayer, Bilayer and Multi particulate systems (Granules, pellets or mini-tablets and combinations thereof)
- Hard Capsules (Hard gelatin or Cellulose capsules with powder in capsule, pellets in capsules) and soft gelatin capsules
- Multi-particulate systems (Pellets and mini tablets)
- Powder in sachet for solution/suspension
Oral Liquids
- Oral solutions with dosing cup
- Oral drops with dosing device
- Oral suspension
- Oral emulsions
Parenterals
- Liquid injectables
- Lyophilized injectables
- Complex injectables
- Ophthalmic and otic solutions
- Nasal solutions ( Sprays and Blow-Fill-Seal)
Topical
- Ointment
- Cream
- Gel
Why Aurigene Pharmaceutical Services?
Services across the product lifecycle
USFDA inspected lab and manufacturing facilities
Experience with advanced formulation technologies
20+ years of experience in formulation
Other Services
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Resources
JULY 02, 2021
Oligonucleotide as a novel class of therapeutic modality
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions
2016
Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market